AN EXTENSION to the PBS
listing for Remicade (infliximab) will
mean that more patients suffering
from fistulising Crohn’s disease will
be able to access the medication.
The new guidelines no longer rely
on the Crohn’s Disease Activity
Index, which is weighted in favour
of patients with luminal disease
rather than perianal disease.
A recent report in the Medical
Journal of Australia found that
about 30% of patients with clinically
significant perianal Crohn’s disease
didn’t qualify for PBS-subsidised
anti-TNF medication under the
previous criteria.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Aug 10
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.